Karachi, In a recent disclosure to shareholders and the public, CITI Pharma Limited has reported a series of significant share transactions executed by one of its top executives, Rizwan Ahmad, who serves as the company's Executive Director. These transactions, which took place on September 20, 2023, have garnered attention within the investment community.

According to the disclosure, Rizwan Ahmad undertook a series of share purchases on the specified date, indicating a strong show of confidence in the company's prospects. The transactions include the following details:

1. Transaction 1:

Name: Rizwan Ahmad (Executive Director)

Date: September 20, 2023

Nature: BUY

Number of Shares: 34,977

Rate: $20.98 per share

Form of Share Certificates: CDC

Market: Ready

2. Transaction 2:

Name: Rizwan Ahmad (Executive Director)

Date: September 20, 2023

Nature: BUY

Number of Shares: 68,651

Rate: $20.99 per share

Form of Share Certificates: CDC

Market: Ready

3. Transaction 3:

Name: Rizwan Ahmad (Executive Director)

Date: September 20, 2023

Nature: BUY

Number of Shares: 43,585

Rate: $21.00 per share

Form of Share Certificates: CDC

Market: Ready

These transactions collectively represent a substantial investment by Rizwan Ahmad in CITI Pharma Limited. The purchases were made on the open market and signify a significant show of confidence in the company's future performance.

Shareholders and market analysts are closely monitoring these developments as insider transactions can often be viewed as a sign of optimism within a company. Such actions by key executives and substantial shareholders can provide valuable insights into the organization's health and future prospects.

Investors and stakeholders will be keeping a keen eye on CITI Pharma Limited in the coming months to assess the potential impact of these transactions on the company's stock performance and overall strategic direction.